Think 24/7 Web Search

Search results

  1. Results from the Think 24/7 Content Network
  2. MDAI - Wikipedia

    en.wikipedia.org/wiki/MDAI

    MDAI ( 5,6-methylenedioxy-2-aminoindane) is a drug developed in the 1990s by a team led by David E. Nichols at Purdue University. It acts as a non- neurotoxic and highly selective serotonin releasing agent (SSRA) in vitro and produces entactogen effects in humans.

  3. 2-Aminoindane - Wikipedia

    en.wikipedia.org/wiki/2-Aminoindane

    2-Aminoindane ( 2-AI) is a research chemical with applications in neurologic disorders and psychotherapy that has also been sold as a designer drug. [1] It acts as a selective substrate for NET and DAT. [2] [3]

  4. MEAI - Wikipedia

    en.wikipedia.org/wiki/MEAI

    MEAI ( 5-methoxy-2-aminoindane or 5-MeO-AI or Chaperon) belongs to the indane family of molecules. Its molecular structure was first mentioned implicitly in a markush structure schema appearing in a patent from 1998. [ 1] It was later explicitly and pharmacologically described in a peer reviewed paper in 2017 by David Nutt and Ezekiel Golan et ...

  5. 3,4-Methylenedioxyamphetamine - Wikipedia

    en.wikipedia.org/wiki/3,4-Methylenedioxyamphetamine

    3,4-Methylenedioxyamphetamine. 3,4-Methylenedioxyamphetamine (also known as MDA and sass) is an empathogen-entactogen, psychostimulant, and psychedelic drug of the amphetamine family that is encountered mainly as a recreational drug. In its pharmacology, MDA is a serotonin–norepinephrine–dopamine releasing agent (SNDRA).

  6. 5-IAI - Wikipedia

    en.wikipedia.org/wiki/5-IAI

    5-Iodo-2-aminoindane ( 5-IAI) is a drug which acts as a releasing agent of serotonin, norepinephrine, and dopamine. [ 2] It was developed in the 1990s by a team led by David E. Nichols at Purdue University. [ 3] 5-IAI fully substitutes for MDMA in rodents and is a putative entactogen in humans. [ 3] Unlike related aminoindane derivatives like ...

  7. MDMAI - Wikipedia

    en.wikipedia.org/wiki/MDMAI

    MDMAI. 5,6-Methylenedioxy-N-methyl-2-aminoindane ( MDMAI ), is a drug developed in the 1990s by a team led by David E. Nichols at Purdue University. It acts as a non- neurotoxic and highly selective serotonin releasing agent (SSRA) in animals and a putative entactogen in humans. [1]

  8. MMAI - Wikipedia

    en.wikipedia.org/wiki/MMAI

    Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Donate; Help; Learn to edit; Community portal; Recent changes; Upload file

  9. Serotonin–norepinephrine–dopamine releasing agent - Wikipedia

    en.wikipedia.org/wiki/Serotonin–norepinephrine...

    A serotonin–norepinephrine–dopamine releasing agent ( SNDRA ), also known as a triple releasing agent ( TRA ), is a type of drug which induces the release of serotonin, norepinephrine / epinephrine, and dopamine in the brain and body. SNDRAs produce euphoriant, entactogen, and psychostimulant effects, and are almost exclusively encountered ...